These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 27655638)
1. Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer. Li J; Huang J; Huang F; Jin Q; Zhu H; Wang X; Chen M Oncotarget; 2016 Nov; 7(45):73638-73650. PubMed ID: 27655638 [TBL] [Abstract][Full Text] [Related]
2. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1 Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762 [TBL] [Abstract][Full Text] [Related]
3. Hsp27 and its expression pattern in diffusely infiltrating astrocytomas. Mäkelä KS; Haapasalo JA; Ilvesaro JM; Parkkila S; Paavonen T; Haapasalo HK Histol Histopathol; 2014 Sep; 29(9):1161-8. PubMed ID: 24599602 [TBL] [Abstract][Full Text] [Related]
4. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients. Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769 [TBL] [Abstract][Full Text] [Related]
5. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605 [TBL] [Abstract][Full Text] [Related]
6. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas. Gousias K; Niehusmann P; Gielen G; Simon M; Boström J J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863 [TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362 [TBL] [Abstract][Full Text] [Related]
8. IDH1 mutation diminishes aggressive phenotype in glioma stem cells. Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585 [TBL] [Abstract][Full Text] [Related]
9. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191 [TBL] [Abstract][Full Text] [Related]
10. Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma. Shayanfar N; Zare-Mirzaie A; Mohammadpour M; Jafari E; Mehrtash A; Emtiazi N; Tajik F J Cancer Res Clin Oncol; 2023 Jul; 149(8):4253-4267. PubMed ID: 36063222 [TBL] [Abstract][Full Text] [Related]
11. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544 [TBL] [Abstract][Full Text] [Related]
12. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor. Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929 [TBL] [Abstract][Full Text] [Related]
13. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1 Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607 [TBL] [Abstract][Full Text] [Related]
16. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas. Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180 [TBL] [Abstract][Full Text] [Related]
17. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling. Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959 [TBL] [Abstract][Full Text] [Related]
18. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas. Ren F; Zhao Q; Huang L; Zheng Y; Li L; He Q; Zhang C; Li F; Maimela NR; Sun Z; Jia Q; Ping Y; Zhang Z; Chen X; Yue Y; Liu S; Cao L; Zhang Y Immunol Cell Biol; 2019 May; 97(5):457-469. PubMed ID: 30575118 [TBL] [Abstract][Full Text] [Related]
19. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies. Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]